Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|AXL pos FLT3 exon 14 ins||acute myeloid leukemia||sensitive||Cytarabine + ONO-7475||Preclinical - Cell culture||Actionable||In a preclinical study, ONO-7475 combined with Cytosar-U (cytarabine) treatment resulted in enhanced reduction in viability and induction of apoptosis in acute myeloid leukemia cell lines expressing AXL and harboring FLT3-ITD in culture (PMID: 28912176).||28912176|
|AXL pos FLT3 exon 14 ins||acute myeloid leukemia||sensitive||ONO-7475||Preclinical - Cell line xenograft||Actionable||In a preclinical study, ONO-7475 treatment inhibited phosphorylation of Flt3, Erk and S6, induced apoptosis and cell cycle arrest, and reduced viability of acute myeloid leukemia cell lines expressing AXL and harboring FLT3-ITD in culture, and increased median survival in a cell line xenograft model (PMID: 28912176).||28912176|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|